AtriCure, Inc. ATRC
AtriCure, Inc. (ATRC) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $534.5M at a -2.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.368 |
| Retained earnings / assets | -0.632 |
| EBIT / assets | -0.014 |
| Equity / liabilities | 3.032 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ATRC | AtriCure, Inc. | 7/9 | 3.44 | — | +14.9% |
| GKOS | GLAUKOS Corp | 2/9 | 0.74 | — | +32.3% |
| BVS | Bioventus Inc. | 8/9 | 0.54 | 35.9 | -0.9% |
| UFPT | UFP TECHNOLOGIES INC | 7/9 | 6 | 28.7 | +19.5% |
| ARAY | ACCURAY INC | 6/9 | -1.53 | — | +2.7% |
| AORT | ARTIVION, INC. | 7/9 | 3.05 | 117.3 | +13.6% |
| MDXG | MIMEDX GROUP, INC. | 5/9 | 8.06 | 12 | +20% |
About AtriCure, Inc.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
FAQ
Is ATRC financially healthy?
AtriCure, Inc.'s Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ATRC pay a dividend?
No, AtriCure, Inc. does not currently pay a dividend.
How profitable is ATRC?
In FY2025, AtriCure, Inc. had a net margin of -2.1% and a return on equity of -2.3%.
What is the analyst price target for ATRC?
The average Wall-Street price target for AtriCure, Inc. is $47.00, about 7.9% above the recent price, from 8 analysts.
Is ATRC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AtriCure, Inc.: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.